Compare SB & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SB | GERN |
|---|---|---|
| Founded | 2007 | 1990 |
| Country | Monaco | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 971.0M | 1.0B |
| IPO Year | 2008 | 1996 |
| Metric | SB | GERN |
|---|---|---|
| Price | $7.82 | $1.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $9.50 | $4.25 |
| AVG Volume (30 Days) | 1.3M | ★ 6.8M |
| Earning Date | 11-24-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.99% | N/A |
| EPS Growth | N/A | ★ 51.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,065,000.00 |
| Revenue This Year | $16.80 | $28.49 |
| Revenue Next Year | N/A | $44.73 |
| P/E Ratio | $16.77 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.23 | $1.04 |
| 52 Week High | $9.31 | $2.01 |
| Indicator | SB | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 39.51 | 36.90 |
| Support Level | $6.20 | $1.08 |
| Resistance Level | $8.05 | $1.26 |
| Average True Range (ATR) | 0.28 | 0.04 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 3.69 | 15.00 |
Safe Bulkers Inc is an international provider of marine drybulk transportation services, transporting bulk cargoes, particularly coal, grain, and iron ore, along international shipping routes for consumers of marine drybulk transportation services. The company employs its vessels on both period time charters and spot time charters, according to the assessment of market conditions, with consumers of marine drybulk transportation services. The company generates almost all of its revenue from Time Charters.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.